Optison is an ultrasound contrast agent available in a ready-to-use formulation, providing the benefits of fast preparation time, ease of use, portability, and flexible dosing. 2 The recommended dose ...

GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands ...

PRINCETON, NJ ─ November 18, 2013 ─ GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ ...

GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres ...

Expanding the approval to pediatric patients is expected to improve the diagnostic accuracy of echocardiograms. The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A ...

The removal of the contraindication to screen for hypersensitivity to blood and blood products is expected to improve workflow efficiency for health care professionals. The Food and Drug ...

Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...

Please provide your email address to receive an email when new articles are posted on . A recent study has demonstrated that echocardiography with a perflutren-based ultrasound contrast agent yielded ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to remove hypersensitivity to ‘blood and blood ...

October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...